James Galloway, MD
Family Medicine · Ayden, NCNPI 1205898426
Payments from drug & device makers
Across 417 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$934
- Novo Nordisk$656
- Sanofi-aventis U.S. LLC$528
- GSK$524
- Amgen$507
- Lilly USA, LLC$370
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,200100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $934 |
| Novo Nordisk | 49 | $656 |
| Sanofi-aventis U.S. LLC | 33 | $528 |
| GSK | 45 | $524 |
| Amgen | 41 | $507 |
| Lilly USA, LLC | 24 | $370 |
| Pfizer | 23 | $345 |
| AbbVie(2 entities) | 20 | $321 |
| Boehringer Ingelheim | 14 | $204 |
| Abbott | 10 | $188 |
| Merck | 13 | $187 |
| Novartis | 10 | $164 |
| Esperion Therapeutics, Inc. | 8 | $132 |
| Eisai Inc. | 9 | $123 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $119 |
| Amarin Pharma, Inc. | 7 | $103 |
| Ironwood Pharmaceuticals, Inc | 7 | $101 |
| Biogen | 5 | $91 |
| Hikma Pharmaceuticals USA | 6 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $80 |
| Astellas Pharma US Inc | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| Kowa Pharmaceuticals America, Inc. | 4 | $49 |
| Genentech USA, Inc. | 2 | $44 |
| Exact Sciences | 2 | $31 |
| Eyevance Pharmaceuticals LLC | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Dexcom, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
How this compares
$6,215 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 102 | $84,635 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 47 | $40,980 |
| FarxigaDapagliflozin Propanediol | 61 | $37,543 |
| TradjentaLinagliptin | 44 | $35,884 |
| JanuviaSitagliptin Phosphate | 34 | $31,603 |
| Tresiba Flextouch U-100Insulin Degludec | 62 | $28,101 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $27,615 |
| OzempicSemaglutide | 32 | $26,652 |
| MounjaroTirzepatide | 25 | $25,688 |
| Repatha SureclickEvolocumab | 27 | $22,330 |
| UbrelvyUbrogepant | 16 | $20,502 |
| JardianceEmpagliflozin | 25 | $17,412 |
| LinzessLinaclotide | 20 | $16,102 |
| Spiriva HandihalerTiotropium Bromide | 12 | $11,577 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $7,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $345 | $84,635102 claims |
| Boehringer IngelheimTradjenta, Jardiance | $204 | $53,29569 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $934 | $52,59894 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $528 | $40,98047 claims |
| AbbVieUbrelvy, Linzess, Savella | $321 | $39,35748 claims |
| MerckJanuvia | $187 | $31,60334 claims |
| GSKTrelegy Ellipta, Shingrix | $524 | $30,51756 claims |
| Novo NordiskOzempic | $656 | $26,65232 claims |
| Lilly USA, LLCMounjaro | $370 | $25,68825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Ayden
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.